Immunovia publishes the Annual Report for 2024
Immunovia AB (IMMNOV: Nasdaq Stockholm) has announced the publication of its Annual Report for 2024. The company specializes in diagnostic solutions focused on increasing pancreatic cancer survival rates through early detection using blood-based testing technology.
Immunovia's primary market is the United States, where an estimated 1.8 million individuals are considered high-risk for pancreatic cancer and could benefit from annual surveillance testing. The company develops tests to detect specific proteins and antibodies that indicate pancreatic cancer development in high-risk individuals, working closely with healthcare providers, experts, and patient advocacy groups.
Immunovia AB (IMMNOV: Nasdaq Stoccolma) ha annunciato la pubblicazione del suo Rapporto Annuale per il 2024. L'azienda è specializzata in soluzioni diagnostiche focalizzate sull'aumento dei tassi di sopravvivenza al cancro pancreatico attraverso la rilevazione precoce utilizzando tecnologie di test basate sul sangue.
Il mercato principale di Immunovia è rappresentato dagli Stati Uniti, dove si stima che 1,8 milioni di individui siano considerati ad alto rischio di cancro pancreatico e potrebbero beneficiare di test di sorveglianza annuali. L'azienda sviluppa test per rilevare proteine specifiche e anticorpi che indicano lo sviluppo del cancro pancreatico in individui ad alto rischio, collaborando strettamente con fornitori di assistenza sanitaria, esperti e gruppi di advocacy dei pazienti.
Immunovia AB (IMMNOV: Nasdaq Estocolmo) ha anunciado la publicación de su Informe Anual para 2024. La empresa se especializa en soluciones diagnósticas centradas en aumentar las tasas de supervivencia del cáncer de páncreas a través de la detección temprana utilizando tecnología de pruebas basadas en sangre.
El mercado principal de Immunovia es Estados Unidos, donde se estima que 1.8 millones de personas son consideradas de alto riesgo para el cáncer de páncreas y podrían beneficiarse de pruebas de vigilancia anuales. La empresa desarrolla pruebas para detectar proteínas específicas y anticuerpos que indican el desarrollo del cáncer de páncreas en individuos de alto riesgo, trabajando en estrecha colaboración con proveedores de atención médica, expertos y grupos de defensa de pacientes.
Immunovia AB (IMMNOV: 나스닥 스톡홀름)는 2024년 연례 보고서의 발행을 발표했습니다. 이 회사는 혈액 기반 검사 기술을 사용하여 조기 발견을 통해 췌장암 생존율을 높이는 데 중점을 둔 진단 솔루션을 전문으로 합니다.
Immunovia의 주요 시장은 미국으로, 약 180만 명의 개인이 췌장암 고위험군으로 간주되며 연간 감시 검사의 혜택을 받을 수 있습니다. 이 회사는 고위험 개인에서 췌장암 발병을 나타내는 특정 단백질과 항체를 감지하는 검사를 개발하고, 의료 제공자, 전문가 및 환자 옹호 단체와 긴밀히 협력하고 있습니다.
Immunovia AB (IMMNOV : Nasdaq Stockholm) a annoncé la publication de son Rapport Annuel pour 2024. L'entreprise se spécialise dans des solutions diagnostiques axées sur l'augmentation des taux de survie au cancer du pancréas grâce à une détection précoce utilisant une technologie de tests sanguins.
Le principal marché d'Immunovia est les États-Unis, où environ 1,8 million de personnes sont considérées comme étant à haut risque de cancer du pancréas et pourraient bénéficier de tests de surveillance annuels. L'entreprise développe des tests pour détecter des protéines spécifiques et des anticorps indiquant le développement du cancer du pancréas chez les individus à haut risque, en collaborant étroitement avec des prestataires de soins de santé, des experts et des groupes de défense des patients.
Immunovia AB (IMMNOV: Nasdaq Stockholm) hat die Veröffentlichung ihres Jahresberichts für 2024 angekündigt. Das Unternehmen ist auf diagnostische Lösungen spezialisiert, die darauf abzielen, die Überlebensraten bei Bauchspeicheldrüsenkrebs durch frühzeitige Erkennung mit blutbasierten Testtechnologien zu erhöhen.
Der Hauptmarkt von Immunovia sind die Vereinigten Staaten, wo schätzungsweise 1,8 Millionen Personen als Hochrisikopatienten für Bauchspeicheldrüsenkrebs gelten und von jährlichen Überwachungsuntersuchungen profitieren könnten. Das Unternehmen entwickelt Tests zur Erkennung spezifischer Proteine und Antikörper, die auf die Entwicklung von Bauchspeicheldrüsenkrebs bei Hochrisikopatienten hinweisen, und arbeitet eng mit Gesundheitsdienstleistern, Experten und Patientenvertretungsgruppen zusammen.
- Large addressable market with 1.8 million potential high-risk individuals in the US
- None.
The annual report can be downloaded in pdf format and is available on Immunovia's website.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Immunovia in brief
Immunovia AB (IMMNOV: Nasdaq Stockholm), is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-publishes-the-annual-report-for-2024,c4129259
The following files are available for download:
Annual Report 2024 |
View original content:https://www.prnewswire.com/news-releases/immunovia-publishes-the-annual-report-for-2024-302418139.html
SOURCE Immunovia AB
FAQ
What is the main focus of Immunovia's (IMMNOV) diagnostic technology?
How many people could benefit from Immunovia's (IMMNOV) pancreatic cancer testing in the USA?
Where are Immunovia's (IMMNOV) shares listed?
When did Immunovia (IMMNOV) publish its latest Annual Report?
